Neoadjuvant combination chemotherapy for unresectable stage III non-small cell lung cancer

被引：1

作者：

Bunn, Paul A., Jr. ^{[1
]}

Gaspar, Laurie E. ^{[2
]}

Weyant, Michael J. ^{[3
]}

Mitchell, John D. ^{[3
]}

机构：

[1] Univ Colorado, Ctr Canc, Dept Med, Denver, CO 80262 USA

[2] Univ Colorado, Ctr Canc, Dept Radiat Oncol, Denver, CO 80262 USA

[3] Univ Colorado, Ctr Canc, Dept Surg, Denver, CO 80262 USA

来源：

CANCER | 2016年 / 122卷 / 05期

关键词：

ADJUVANT BEVACIZUMAB; TRIAL; CONSOLIDATION; CONCURRENT; THERAPY; CARBOPLATIN; DOCETAXEL; PLACEBO;

D O I：

10.1002/cncr.29797

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Neoadjuvant chemotherapy and chemoradiation therapy can be considered for patients with potentially resectable stage III Non-Small cell lung cancer. The use of antiangiogenic agents, the best systemic therapy, and the best radiation field and dose require further study.

引用

页码：674 / 675

页数：2

共 14 条

[1] Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data [J].

Auperin, A. ;

Le Chevalier, T. ;

Le Pechoux, C. ;

Pignon, J. P. ;

Tribodet, H. ;

Burdett, S. ;

Stewart, L. A. ;

Tierney, J. F. ;

Stephens, R. J. ;

Arriagada, R. ;

Higgins, J. P. ;

Johnson, D. H. ;

van Meerbeeck, J. ;

Parmar, M. K. B. ;

Souhami, R. L. ;

Bergman, B. ;

Dautzenberg, B. ;

Douillard, J. Y. ;

Dunant, A. ;

Endo, C. ;

Girling, D. J. ;

Imaizumi, M. ;

Kato, H. ;

Keller, S. M. ;

Kimura, H. ;

Knuuttila, A. ;

Kodama, K. ;

Komaki, R. ;

Kris, M. G. ;

Lad, T. ;

Mineo, T. ;

Park, J. H. ;

Piantadosi, S. ;

Pyrhonen, S. ;

Rosell, R. ;

Scagliotti, G. V. ;

Seymour, L. W. ;

Shepherd, F. A. ;

Spiro, S. G. ;

Strauss, G. M. ;

Sylvester, R. ;

Tada, H. ;

Tanaka, F. ;

Torri, V. ;

Wada, H. ;

Waller, D. ;

Xu, G. C. .

LANCET, 2010, 375 (9722) :1267-1277

[2] Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study [J].

Bradley, Jeffrey D. ;

Paulus, Rebecca ;

Komaki, Ritsuko ;

Masters, Gregory ;

Blumenschein, George ;

Schild, Steven ;

Bogart, Jeffrey ;

Hu, Chen ;

Forster, Kenneth ;

Magliocco, Anthony ;

Kavadi, Vivek ;

Garces, Yolanda I. ;

Narayan, Samir ;

Iyengar, Puneeth ;

Robinson, Cliff ;

Wynn, Raymond B. ;

Koprowski, Christopher ;

Meng, Joanne ;

Beitler, Jonathan ;

Gaur, Rakesh ;

Curran, Walter, Jr. ;

Choy, Hak .

LANCET ONCOLOGY, 2015, 16 (02) :187-199

[3] Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data [J].

Burdett, Sarah ;

Rydzewska, Larysa H. M. ;

Tierney, Jayne F. ;

Auperin, Anne ;

Le Pechoux, Cecile ;

Le Chevalier, Thierry ;

Pignon, Jean-Pierre .

LANCET, 2014, 383 (9928) :1561-1571

[4] Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial [J].

Cameron, David ;

Brown, Julia ;

Dent, Rebecca ;

Jackisch, Christian ;

Mackey, John ;

Pivot, Xavier ;

Steger, Guenther G. ;

Suter, Thomas M. ;

Toi, Masakazu ;

Parmar, Mahesh ;

Laeufle, Rita ;

Im, Young-Hyuck ;

Romieu, Gilles ;

Harvey, Vernon ;

Lipatov, Oleg ;

Pienkowski, Tadeusz ;

Cottu, Paul ;

Chan, Arlene ;

Im, Seock-Ah ;

Hall, Peter S. ;

Bubuteishvili-Pacaud, Lida ;

Henschel, Volkmar ;

Deurloo, Regula J. ;

Pallaud, Celine ;

Bell, Richard .

LANCET ONCOLOGY, 2013, 14 (10) :933-942

[5] Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study [J].

Corrie, Pippa G. ;

Marshall, Andrea ;

Dunn, Janet A. ;

Middleton, Mark R. ;

Nathan, Paul D. ;

Gore, Martin ;

Davidson, Neville ;

Nicholson, Steve ;

Kelly, Charles G. ;

Marples, Maria ;

Danson, Sarah J. ;

Marshall, Ernest ;

Houston, Stephen J. ;

Board, Ruth E. ;

Waterston, Ashita M. ;

Nobes, Jenny P. ;

Harries, Mark ;

Kumar, Satish ;

Young, Gemma ;

Lorigan, Paul .

LANCET ONCOLOGY, 2014, 15 (06) :620-630

[6]

Kelly K, 2015, J CLIN ONCOL, DOI [10.1002/JCO.2015.61.8918, DOI 10.1002/JCO.2015.61.8918]

[7] Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023 [J].

Kelly, Karen ;

Chansky, Kari ;

Gaspar, Laurie E. ;

Albain, Kathy S. ;

Jett, James ;

Ung, Yee C. ;

Lau, Derick H. M. ;

Crowley, John J. ;

Gandara, David R. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) :2450-2456

[8] Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001) [J].

Ou, Wei ;

Li, Ning ;

Wang, Si-Yu ;

Li, Jian ;

Liu, Qian-Wen ;

Huang, Qun-Ai ;

Wang, Bao-Xiao .

CANCER, 2016, 122 (05) :740-747

[9] Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) [J].

Reck, M. ;

von Pawel, J. ;

Zatloukal, P. ;

Ramlau, R. ;

Gorbounova, V. ;

Hirsh, V. ;

Leighl, N. ;

Mezger, J. ;

Archer, V. ;

Moore, N. ;

Manegold, C. .

ANNALS OF ONCOLOGY, 2010, 21 (09) :1804-1809

[10]

Sandler A, 2007, NEW ENGL J MED, V356, P318

← 1 2 →